In 2023, the alimentary tract and metabolism medicine sales in Canada stood at approximately 7.8 billion Canadian Dollars. The forecasted data from 2024 onwards indicates a robust and consistent growth pattern over the five-year period. Year-on-year percentage increases are as follows: 2024 to 2025 shows a rise of 10.14%, 2025 to 2026 a growth of 9.13%, 2026 to 2027 a gain of 8.24%, and 2027 to 2028 a jump of 7.64%. Over the five-year period, the compound annual growth rate (CAGR) is 9.47%.
Future trends to watch for include advancements in personalized medicine, new therapeutic options for digestive and metabolic disorders, and the impact of an aging population increasing demand for these medications.
